HMB-001 is a novel bispecific antibody designed to be the first prophylactic treatment for Glanzmann’s thrombasthenia (GT) and other debilitating bleeding disorders. Phase 1 was successfully completed in the UK; Hemab plans additional sites in Europe and the U.S. for Phase 2. The U.S. FDA has cleared the Investigational New Drug (IND) application and granted Fast Track Designation to HMB-001 for the treatment of GT.
First Patient Dosed in Phase 2 Clinical Study with Hemab Therapeutics' "HMB-001" for the Treatment of Glanzmann's thrombasthenia